What Genesis Therapeutics does
Genesis Therapeutics (now operating as Genesis Molecular AI) is an AI-for-small-molecule drug discovery company building a molecular AI “platform” and foundation models intended to speed up the generate–predict–interrogate–decide cycle used by drug hunters. Its stated approach combines (1) generative/proposal models, (2) protein–ligand structure prediction via its Pearl foundation model, and (3) additional property prediction and simulation/physics components inside its GEMS platform to evaluate candidate molecules and guide design toward potency, selectivity, and ADME characteristics.
More
The company positions GEMS as an end-to-end operating system that integrates foundation models with agents/workflow tooling for chemists, where the platform runs design workflows and produces candidate lists and predicted properties for subsequent synthesis decisions. Genesis’s commercial strategy centers on deploying GEMS both internally (in its own discovery pipeline) and with major pharma partners. In 2025–2026, it publicly highlighted collaboration expansion with Incyte (including partner data use for training), and it also describes NVIDIA collaboration to optimize computational methods used in its platform and foundation models.